scPharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

• scPharmaceuticals Inc SCPH.OQ reported a quarterly adjusted loss of 44 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -44 cents. The mean expectation of five analysts for the quarter was for a loss of 30 cents per share. Wall Street expected results to range from -37 cents to -24 cents per share.

• Revenue rose 92.6% to $11.75 million from a year ago; analysts expected $15.41 million.

• scPharmaceuticals Inc's reported EPS for the quarter was a loss of 44 cents​.

• The company reported a quarterly loss of $19.74 million.

• scPharmaceuticals Inc shares had risen by 38.1% this quarter and gained 48.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 9.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for scPharmaceuticals Inc is $12.00, about 58.3% above its last closing price of $5.01

This summary was machine generated from LSEG data August 8 at 03:06 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)